- Previous Close
1,735.45 - Open
1,727.15 - Bid 1,698.30 x --
- Ask 1,701.20 x --
- Day's Range
1,681.25 - 1,732.90 - 52 Week Range
1,376.75 - 1,960.20 - Volume
194,187 - Avg. Volume
51,563 - Market Cap (intraday)
4.072T - Beta (5Y Monthly) 0.54
- PE Ratio (TTM)
35.56 - EPS (TTM)
47.72 - Earnings Date May 20, 2025 - May 24, 2025
- Forward Dividend & Yield 15.50 (0.89%)
- Ex-Dividend Date Feb 6, 2025
- 1y Target Est
2,051.84
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It provides APIs for anti-cancers, peptides, steroids, hormones, and immunosuppressant drugs. In addition, the company offers generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, and antiretrovirals medications, as well as over-the-counter products. The company was founded in 1983 and is headquartered in Mumbai, India.
www.sunpharma.com43,000
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: SUNPHARMA.BO
View MorePerformance Overview: SUNPHARMA.BO
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SUNPHARMA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SUNPHARMA.BO
View MoreValuation Measures
Market Cap
4.16T
Enterprise Value
3.98T
Trailing P/E
36.38
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.15
Price/Book (mrq)
6.02
Enterprise Value/Revenue
7.80
Enterprise Value/EBITDA
24.67
Financial Highlights
Profitability and Income Statement
Profit Margin
22.16%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
516.02B
Net Income Avi to Common (ttm)
114.34B
Diluted EPS (ttm)
47.72
Balance Sheet and Cash Flow
Total Cash (mrq)
201.22B
Total Debt/Equity (mrq)
3.71%
Levered Free Cash Flow (ttm)
--